This excerpt taken from the BMY 8-K filed Jan 28, 2010.
Strong Operational and Strategic Performance in Fourth Quarter Caps Transformative 2009
(NEW YORK, January 28, 2010) Bristol-Myers Squibb Company (NYSE: BMY) today announced strong fourth quarter sales and earnings growth driven by the companys continued operational and strategic execution.
Our top-line sales growth and improved operating margins reflect excellent execution across our company, said James M. Cornelius, chairman and chief executive officer. As a result, we have strengthened our financial position and are well prepared to continue delivering on our BioPharma strategy in 2010. In 2009, we completed strategic initiatives such as splitting off Mead Johnson, acquiring Medarex and extending our Abilify commercialization agreement with Otsuka; all of which significantly address present and future challenges.
While fundamentally transforming our company over the past year, we were able to grow our key franchises, launch new medicines and indications, advance a diverse, differentiated, robust pipeline and embed productivity into our corporate DNA. Bristol-Myers Squibb is now truly a focused biopharmaceutical company which continues to deliver shareholder value and helps patients prevail over serious diseases.